A feasibility study to determine if it is possible to perform a safe, adequately powered, and affordable multi-centre study in critically ill children comparing current practice of liberal targets for systemic oxygen levels with more conservative targets.
Around 19,000 critically ill children are admitted to paediatric intensive care units (PICU) each year in the UK. A large number of these children need breathing support, and this is usually provided through an invasive machine called a 'ventilator'. Clinicians make decisions for treatment based on how much oxygen their patient has in their blood (this is called oxygen saturation or oxygenation) and currently the amount of oxygen critically ill children need is not fully understood. This means that some clinicians use a lower oxygen saturation target, and others, a higher target. This may be problematic as research in neonates (babies) and adults has shown that oxygen saturation levels can influence a patient's chance of survival, how long they stay in hospital and healthcare costs. Response to oxygen is different in babies, children and adults. This means that the results from the neonatal and adult research are unlikely to be valid or applicable in children due to age-related differences. Urgent high quality clinical evidence is therefore needed to inform on the best targets of oxygenation during critical illness in children. As large clinical trials are expensive to conduct, it is important to demonstrate that a large-scale trial can be done and that the different components of a trial can all work together. Therefore, the Oxy-PICU study is a 'pilot randomised clinical trial' (a smaller version of the trial we would like to conduct) and will test the feasibility and safety of conducting a large scale trial comparing a restrictive oxygen saturation target (88-92%) with a more liberal oxygen saturation target (\>94%). Oxy-PICU will also collect blood and urine samples to allow for in depth study of the biology of the different oxygenation targets. The pilot trial will take place at three PICUs (two in London and one in Southampton) and aims to include between 115-125 eligible children over six months. Given the emergency nature of these children and the need to provide immediate care, informed consent will be sought after the children are entered into the study (this is known as deferred consent).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining \>94%.
Great Ormond Street Hospital for Children
London, United Kingdom
St Mary's Hospital
London, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Number of eligible patients recruited per site per month
Time frame: Baseline
Proportion of parents/legal representatives refusing deferred consent
Time frame: Through study completion, an average of 24 hours
Proportion of eligible patients randomised
Time frame: Baseline
Distribution of time to randomisation
Time frame: Baseline
Proportion of systemic oxygen saturations within the target range in each group
Time frame: Through study completion, an average of 72 hours
Proportion of patients in each arm requiring other treatments influencing tissue oxygen delivery (blood transfusion, inotropic support)
Time frame: Through study completion, an average of 72 hours
Length of ventilation - proportion of randomised patients with outcome available in each group
Time frame: Through study completion, an average of 2 days
Length of ventilation - mean (standard deviation) in each group
Time frame: Through study completion, an average of 2 days
Length of ventilation - median and quartiles in each group.
Time frame: Through study completion, an average of 2 days
Observed adverse events
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time taken for data collection and entry
Time frame: 28 days
Measurement of ischemia-modified albumin (plasma)
Time frame: 72 hours
Measurement of malondialdehyde (plasma)
Time frame: 72 hours
Measurement of total antioxidant status (plasma)
Time frame: 72 hours
Length of PICU stay - proportion of randomised patients with outcome available in each group
Time frame: Through study completion, an average of 2 days
Length of PICU stay - mean (standard deviation) in each group.
Time frame: Through study completion, an average of 2 days
Length of PICU stay - median and quartiles in each group.
Time frame: Through study completion, an average of 2 days
Hospital mortality - proportion of randomised patients with outcome available in each group
Time frame: Through study completion, an average of 2 days
Hospital mortality - number (percentage) in each group.
Time frame: Through study completion, an average of 2 days
PICU mortality - proportion of randomised patients with outcome available in each group
Time frame: Through study completion, an average of 2 days
PICU mortality - number (percentage) in each group.
Time frame: Through study completion, an average of 2 days
Days of organ specific support - proportion of randomised patients with outcome available in each group
Time frame: Through study completion, an average of 2 days
Days of organ specific support - mean (standard deviation) in each group
Time frame: Through study completion, an average of 2 days
Days of organ specific support - median and quartiles in each group
Time frame: Through study completion, an average of 2 days
Measurement of hypoxia-inducible factor-1 alpha mRNA expression (leukocytes)
Time frame: 72 hours